Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identifying RAGE inhibitors as potential therapeutics for Alzheimer’s disease via integrated in-silico approaches

22 May 2025

Abstract excerpt

Alzheimer's disease is a neurodegenerative disorder characterized by two hallmarks: amyloid beta plaques and neurofibrillary tangles. The receptor for advanced glycation end products (RAGE) is a multi-ligand receptor involved in the pathophysiology of various diseases including cancer, diabetes, cardiovascular diseases, and Alzheimer's disease (AD). Therefore, targeting RAGE could be an effective strategy to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Glycation End Products research
Share to Computational Drug Discovery Methods
Share to Natural Antidiabetic Agents Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40404684
DOI: 10.1038/s41598-025-01271-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identifying RAGE inhibitors as potential therapeutics for Alzheimer’s disease via integrated in-silico approachesPMID 40404684Read ↗

G82S RAGE polymorphism influences amyloid-RAGE interactions relevant in Alzheimer's disease pathology.Semantic proximity Read ↗

Molecular Characteristics of RAGE and Advances in Small-Molecule InhibitorsSemantic proximity Read ↗

RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and DiseaseSemantic proximity Read ↗

RAGE: The Beneficial and Deleterious Effects by Diverse Mechanisms of ActionsSemantic proximity Read ↗

Current Evidence on the Involvement of RAGE-Diaph1 Signaling in the Pathology and Treatment of Neurodegenerative Diseases – an OverviewSemantic proximity Read ↗

Identification of potential neuroprotective compound from Ganoderma lucidum extract targeting microtubule affinity regulation kinase 4 involved in Alzheimer's disease through molecular dynamics simulation and MMGBSASemantic proximity Read ↗

Network Pharmacology-guided Identification and Molecular Validation of Multi-Target Phytoconstituents from Gmelina arborea against Alzheimer’s DiseaseSemantic proximity Read ↗

Natural inhibitors of DYRK1A as drug candidates against Alzheimer Disease: QSAR, molecular docking, molecular dynamics simulation and drug evaluation assessmentSemantic proximity Read ↗

Network Pharmacology-guided Identification and Molecular Validation of Multi-Target Phytoconstituents from Gmelina arborea against Alzheimer’s DiseaseSemantic proximity Read ↗

Polyphenols in the Pipeline: Network-Based Docking, Molecular Dynamics and ADMET Studies of Flavonoids against Alzheimer’s diseaseSemantic proximity Read ↗

Molecular docking studies and molecular dynamic simulation analysis: To identify novel ATP-competitive inhibition of Glycogen synthase kinase-3β for Alzheimer’s diseaseSemantic proximity Read ↗

Identification of dual inhibitors against BACE1 and GSK-3β for the treatment of Alzheimer’s disease: An in silico-based approachSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.